Intelligent Bio Solutions (INBS) will present its Pharmacokinetic, or PK, study data at the Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo July 27-31 in Chicago. The PK study collected human fingerprint sweat specimens for laboratory analysis and used INBS’s Intelligent Fingerprinting Drug Screening System. Study data showed that fingerprint sweat mirrors the rate and extent of codeine found in blood and saliva, making it a strong indicator of codeine ingestion. The company’s Drug Screening System is designed to support accurate, dignified, and efficient testing in workplace, treatment, and justice settings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- IBS, Spjotgard drive adoption of fingerprint drug testing across Scandinavia
- INBS announces MWS plan to implement its Drug Screening System
- Intelligent Bio Solutions expands U.S. forensic market presence
- Intelligent Bio Solutions (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25
- Intelligent Bio Solutions (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows